As part of the 2021 growth strategy, the acquisition spearheads the growth of Clinical business in accordance with the global Clinical market.
Navitas Life Sciences, a TAKE Solutions Enterprise, will acquire Life Sciences services player, DataCeutics, in North America.
As part of the 2021 growth strategy, the acquisition spearheads the growth of Clinical business in accordance with the global Clinical market. This market is expected to reach $32.9 billion by 2020.
Through this acquisition, Navitas Life Sciences is planning to complement DataCeutics' capabilities with its own AI-driven clinical platform and near real-time data insights and analytics for delivering improved outcomes to clients across safety, quality, compliance, cycle time and cost.
Dr Krishnan Rajagopalan, Chief Growth Officer, Navitas Life Sciences said, "We are delighted to begin 2019 on a high note with this key acquisition. DataCeutics strengthens our capabilities in Data Sciences and FSP / BPO services and widens our therapeutic expertise in Cardiology, Oncology, Pulmonology, CNS, Infectious diseases etc. The addition of these competencies translates to business expansion in North American, European and Asian markets."
"We are looking forward to bolstering the Clinical business further translating to a healthier pipeline in the coming quarters," he added.